4,314 Shares in AbbVie Inc. $ABBV Bought by Stoneridge Investment Partners LLC

Stoneridge Investment Partners LLC bought a new position in AbbVie Inc. (NYSE:ABBV) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 4,314 shares of the company’s stock, valued at approximately $1,083,000. AbbVie makes up 0.7% of Stoneridge Investment Partners LLC’s investment portfolio, making the stock its 28th largest holding.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC increased its holdings in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares during the period. Schnieders Capital Management LLC. boosted its stake in AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares during the period. Ieq Capital LLC grew its position in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after purchasing an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC raised its holdings in shares of AbbVie by 117.3% during the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after buying an additional 612,702 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Price Performance

ABBV opened at $265.56 on Wednesday. The business has a 50 day moving average price of $250.20 and a two-hundred day moving average price of $228.12. The company has a market capitalization of $469.18 billion, a price-to-earnings ratio of 75.02, a price-to-earnings-growth ratio of 0.88 and a beta of 0.30. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $267.47.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the firm earned $2.97 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts expect that AbbVie Inc. will post 14.06 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Wednesday, July 15th. AbbVie’s payout ratio is presently 195.48%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. BNP Paribas Exane lifted their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. BMO Capital Markets boosted their price target on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Cantor Fitzgerald increased their price target on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Finally, Wells Fargo & Company raised their price target on AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a report on Monday, August 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $275.95.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Humira replacement strategy is gaining credibility: second-quarter revenue rose 10.2% to $16.99 billion, led by immunology products and supported by neuroscience. This suggests Skyrizi, Rinvoq and other newer medicines are more than offsetting Humira’s biosimilar-related decline. AbbVie’s Humira Replacement Strategy Is Working
• Positive Sentiment: New lung-cancer data for investigational treatments ABBV-1480, ABBV-706 and Temab-A point to potentially meaningful future growth in oncology. Reported response rates and manageable safety profiles strengthen the case for AbbVie’s longer-term pipeline, though the programs remain dependent on additional clinical results and approvals. Is AbbVie Quietly Rebalancing Its Growth Story Around Oncology Innovation?
• Positive Sentiment: Several investment managers increased their AbbVie holdings, including Convergence Financial, which nearly doubled its position, and Donaldson Capital Management, which modestly raised its stake. These filings provide a supportive institutional signal but are not major earnings catalysts. Convergence Financial Increased Its AbbVie Holdings
• Neutral Sentiment: In comparisons with Eli Lilly, AbbVie offers a more established cash-generating portfolio and attractive pipeline opportunities, while Lilly has stronger headline growth prospects. The debate highlights AbbVie’s balance between income, stability and pipeline execution rather than a clear near-term catalyst. LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
• Negative Sentiment: Second-quarter oncology sales declined 2.4% as Imbruvica continued to weaken. Growth from Venclexta and newer medicines partly offset the pressure, but the result underscores ongoing reliance on successful launches and pipeline products to revive the franchise. How Did AbbVie’s Oncology Sales Hold Up in Q2?

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.